In vitro and in vivo antibacterial activity of tigecycline against Vibrio vulnificus

Hung Jen Tang, Chi Chung Chen, Chih Cheng Lai, Chun Cheng Zhang, Tzu Chieh Weng, Yu Hsin Chiu, Han Siong Toh, Shyh Ren Chiang, Wen Liang Yu, Wen Chien Ko, Yin Ching Chuang

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background/purpose: The aim of this study is to investigate the role of tigecycline in Vibrio vulnificus infection. Methods: Eight randomly selected clinical V. vulnificus isolates were studied to obtain the minimal inhibitory concentrations (MICs) of minocycline, cefotaxime, and tigecycline, and the time-kill curves of tigecycline alone or in combination with other drugs. A peritonitis mouse model was used for the evaluation of the therapeutic efficacy of tigecycline alone or cefotaxime in combination with minocycline or tigecycline. Results: The MIC of minocycline, cefotaxime, and tigecycline for eight clinical V. vulnificus isolates was 0.06-0.12 μg/mL, 0.03-0.06 μg/mL, and 0.03-0.06 μg/mL, respectively. In time-killing studies, at the concentration of 1 × MIC, the inhibitory effect of tigecycline persisted for 24 hours in five of eight isolates. With 2 × MIC and trough level, the inhibitory effect was noted in all isolates for 24 hours. With the combination of minocycline plus cefotaxime and tigecycline plus cefotaxime at 1/2 × MIC, the bactericidal effect was noted in 25% and 62.5% of eight isolates and synergism in 50% and 75% of isolates. With a low (1.25 × 105 CFU/mL) inoculum, all infected mice survived with tigecycline alone, tigecycline plus cefotaxime, or minocycline plus cefotaxime on the 14th day. At the inoculum of 1.25 × 106 CFU, the survival rate was 33.3% on the 14th day in the tigecycline plus cefotaxime-treated group, but none of the mice treated by tigecycline alone or minocycline plus cefotaxime survived (33.3% vs. 0%, p = 0.01 by Fisher's exact test). Conclusion: Our in vitro combination and animal studies indicate that tigecycline could be an option for the treatment of invasive V. vulnificus infections.

Original languageEnglish
Pages (from-to)76-81
JournalJournal of Microbiology, Immunology and Infection
Volume51
Issue number1
DOIs
Publication statusPublished - Feb 1 2018
Externally publishedYes

Keywords

  • Killing effects
  • Tigecycline
  • Vibrio vulnificus

ASJC Scopus subject areas

  • Microbiology (medical)
  • Immunology and Allergy
  • Immunology and Microbiology(all)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'In vitro and in vivo antibacterial activity of tigecycline against Vibrio vulnificus'. Together they form a unique fingerprint.

  • Cite this

    Tang, H. J., Chen, C. C., Lai, C. C., Zhang, C. C., Weng, T. C., Chiu, Y. H., Toh, H. S., Chiang, S. R., Yu, W. L., Ko, W. C., & Chuang, Y. C. (2018). In vitro and in vivo antibacterial activity of tigecycline against Vibrio vulnificus. Journal of Microbiology, Immunology and Infection, 51(1), 76-81. https://doi.org/10.1016/j.jmii.2016.04.009